Femasys (FEMY) Competitors $1.06 +0.05 (+4.95%) Closing price 04:00 PM EasternExtended Trading$1.05 -0.01 (-0.94%) As of 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock FEMY vs. LUCD, INFU, ICAD, OBIO, MGRM, MBOT, GUTS, EDAP, NSPR, and FONRShould you be buying Femasys stock or one of its competitors? The main competitors of Femasys include Lucid Diagnostics (LUCD), InfuSystem (INFU), iCAD (ICAD), Orchestra BioMed (OBIO), Monogram Orthopaedics (MGRM), Microbot Medical (MBOT), Fractyl Health (GUTS), Edap Tms (EDAP), InspireMD (NSPR), and FONAR (FONR). These companies are all part of the "medical equipment" industry. Femasys vs. Lucid Diagnostics InfuSystem iCAD Orchestra BioMed Monogram Orthopaedics Microbot Medical Fractyl Health Edap Tms InspireMD FONAR Lucid Diagnostics (NASDAQ:LUCD) and Femasys (NASDAQ:FEMY) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations. Do institutionals and insiders hold more shares of LUCD or FEMY? 74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 6.8% of Lucid Diagnostics shares are owned by company insiders. Comparatively, 12.3% of Femasys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has better valuation & earnings, LUCD or FEMY? Femasys has lower revenue, but higher earnings than Lucid Diagnostics. Femasys is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLucid Diagnostics$4.17M34.09-$52.67M-$1.34-0.98Femasys$1.70M16.19-$14.25M-$0.91-1.11 Do analysts rate LUCD or FEMY? Lucid Diagnostics presently has a consensus price target of $3.50, suggesting a potential upside of 166.16%. Femasys has a consensus price target of $8.67, suggesting a potential upside of 758.09%. Given Femasys' higher possible upside, analysts clearly believe Femasys is more favorable than Lucid Diagnostics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lucid Diagnostics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Femasys 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is LUCD or FEMY more profitable? Lucid Diagnostics has a net margin of -1,069.87% compared to Femasys' net margin of -1,435.77%. Lucid Diagnostics' return on equity of 0.00% beat Femasys' return on equity.Company Net Margins Return on Equity Return on Assets Lucid Diagnostics-1,069.87% N/A -123.54% Femasys -1,435.77%-141.49%-82.30% Which has more risk and volatility, LUCD or FEMY? Lucid Diagnostics has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500. Comparatively, Femasys has a beta of -2.52, indicating that its stock price is 352% less volatile than the S&P 500. Does the MarketBeat Community favor LUCD or FEMY? Lucid Diagnostics received 4 more outperform votes than Femasys when rated by MarketBeat users. However, 74.51% of users gave Femasys an outperform vote while only 68.85% of users gave Lucid Diagnostics an outperform vote. CompanyUnderperformOutperformLucid DiagnosticsOutperform Votes4268.85% Underperform Votes1931.15% FemasysOutperform Votes3874.51% Underperform Votes1325.49% Does the media favor LUCD or FEMY? In the previous week, Lucid Diagnostics had 6 more articles in the media than Femasys. MarketBeat recorded 6 mentions for Lucid Diagnostics and 0 mentions for Femasys. Lucid Diagnostics' average media sentiment score of -0.24 beat Femasys' score of -0.35 indicating that Lucid Diagnostics is being referred to more favorably in the media. Company Overall Sentiment Lucid Diagnostics Neutral Femasys Neutral SummaryLucid Diagnostics beats Femasys on 13 of the 19 factors compared between the two stocks. Get Femasys News Delivered to You Automatically Sign up to receive the latest news and ratings for FEMY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FEMY vs. The Competition Export to ExcelMetricFemasysSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.51M$4.41B$5.31B$8.42BDividend YieldN/A43.63%5.21%4.10%P/E Ratio-1.2529.2326.7819.69Price / Sales16.1965.60386.97118.34Price / CashN/A51.0838.2534.62Price / Book1.196.206.744.50Net Income-$14.25M$67.60M$3.23B$248.32M7 Day Performance-5.61%-0.72%1.49%-0.03%1 Month Performance-17.21%18.00%11.47%12.72%1 Year Performance-22.31%21.13%16.57%7.38% Femasys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FEMYFemasys2.291 of 5 stars$1.06+5.0%$8.67+717.6%-21.1%$28.87M$1.70M-1.3130LUCDLucid Diagnostics3.2022 of 5 stars$1.10-2.7%$3.50+218.2%+46.2%$115.92M$4.35M-0.9670Analyst DowngradeGap UpINFUInfuSystem2.4543 of 5 stars$5.48+2.0%$13.00+137.2%N/A$115.17M$134.86M91.35410Positive NewsHigh Trading VolumeICADiCAD0.297 of 5 stars$3.71+3.1%N/A+134.4%$101.83M$19.61M-28.54140Analyst ForecastGap UpHigh Trading VolumeOBIOOrchestra BioMed2.8247 of 5 stars$2.65flat$14.20+435.8%-46.6%$101.53M$2.64M-1.654Gap UpMGRMMonogram Orthopaedics3.0946 of 5 stars$2.63-1.5%$5.40+105.3%+40.7%$92.81M$364,999.00-5.6028Gap UpMBOTMicrobot Medical1.8242 of 5 stars$2.55+1.2%$9.00+252.9%+156.6%$88.60MN/A-3.1920News CoveragePositive NewsEarnings ReportGap UpGUTSFractyl Health1.704 of 5 stars$1.71+5.6%$11.00+543.3%-74.7%$83.75M$93,000.00-0.14102Gap UpEDAPEdap Tms1.821 of 5 stars$2.15-3.2%$8.50+295.3%-71.0%$79.77M$64.12M-3.31230Earnings ReportAnalyst RevisionNSPRInspireMD2.2389 of 5 stars$2.58-0.8%$4.50+74.4%-4.7%$79.04M$7.01M-3.4450FONRFONAR1.787 of 5 stars$12.37-0.2%N/A-4.9%$76.83M$101.57M10.76480News CoverageEarnings ReportAnalyst Upgrade Related Companies and Tools Related Companies Lucid Diagnostics Alternatives InfuSystem Alternatives iCAD Alternatives Orchestra BioMed Alternatives Monogram Orthopaedics Alternatives Microbot Medical Alternatives Fractyl Health Alternatives Edap Tms Alternatives InspireMD Alternatives FONAR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FEMY) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Femasys Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Femasys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FEMY Stock Free FEMY Stock Alerts